NDAORALTABLET
Approved
Mar 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
9
Data completeness
6/8 — Strong
DETROL (tolterodine tartrate) by Viatris (2) is clinical pharmacology tolterodine is a competitive muscarinic receptor antagonist. Approved for overactive bladder. First approved in 1998.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Tolterodine tartrate (DETROL) is an oral small-molecule muscarinic receptor antagonist approved in 1998 for overactive bladder. It works by blocking cholinergic receptors in the bladder to reduce involuntary contractions and increase residual urine volume. The drug is metabolized to an active 5-hydroxymethyl metabolite that contributes significantly to therapeutic effect.
$0.099MPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with minimal Part D presence; brand team likely focused on maintenance rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Tolterodine is a competitive muscarinic receptor antagonist. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors. After oral administration, tolterodine is metabolized in the liver, resulting in the formation of the 5-hydroxymethyl…
Worked on DETROL at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.